The University of Chicago Header Logo

Connection

Marina Chiara Garassino to Antibodies, Monoclonal

Back to Details
This is a "connection" page, showing publications Marina Chiara Garassino has written about Antibodies, Monoclonal.
Marina Chiara Garassino
Connection Strength
3.079
Antibodies, Monoclonal
  1. Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable stage III non-small-cell lung cancer. Future Oncol. 2021 Apr; 17(10):1165-1184.
    View in: PubMed
    Score: 0.465
  2. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. Lancet Oncol. 2018 04; 19(4):521-536.
    View in: PubMed
    Score: 0.380
  3. Should KRAS mutations be considered an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab? J Clin Oncol. 2008 May 20; 26(15):2600; author reply 2601-2.
    View in: PubMed
    Score: 0.192
  4. Bevacizumab for non-small-cell lung cancer. N Engl J Med. 2007 Mar 29; 356(13):1373; author reply 1374-5.
    View in: PubMed
    Score: 0.178
  5. Development and clinical indications of cetuximab. Int J Biol Markers. 2007 Jan-Mar; 22(1 Suppl 4):S40-6.
    View in: PubMed
    Score: 0.175
  6. DARES: A Phase II Trial of Durvalumab and Ablative Radiation in Extensive-Stage Small Cell Lung Cancer. Clin Lung Cancer. 2024 Dec; 25(8):e448-e452.
    View in: PubMed
    Score: 0.148
  7. Durvalumab ± Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden. Clin Cancer Res. 2024 02 16; 30(4):824-835.
    View in: PubMed
    Score: 0.143
  8. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2021 01; 22(1):51-65.
    View in: PubMed
    Score: 0.115
  9. Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study. Lung Cancer. 2020 09; 147:137-142.
    View in: PubMed
    Score: 0.111
  10. Impact of Patient Characteristics, Prior Therapy, and Sample Type on Tumor Cell Programmed Cell Death Ligand 1 Expression in Patients with Advanced NSCLC Screened for the ATLANTIC Study. J Thorac Oncol. 2019 08; 14(8):1390-1399.
    View in: PubMed
    Score: 0.103
  11. Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out. Cancer Treat Rev. 2019 May; 75:39-51.
    View in: PubMed
    Score: 0.102
  12. Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP). Ann Oncol. 2019 02 01; 30(2):161-165.
    View in: PubMed
    Score: 0.101
  13. Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study. Lancet Oncol. 2018 11; 19(11):1468-1479.
    View in: PubMed
    Score: 0.098
  14. Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH). J Clin Oncol. 2017 Aug 20; 35(24):2781-2789.
    View in: PubMed
    Score: 0.090
  15. Immune Checkpoint Blockade: A New Era for Non-Small Cell Lung Cancer. Curr Oncol Rep. 2016 09; 18(9):59.
    View in: PubMed
    Score: 0.085
  16. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med. 2015 Jul 09; 373(2):123-35.
    View in: PubMed
    Score: 0.078
  17. Risk/benefit profile of bevacizumab in metastatic colon cancer: a systematic review and meta-analysis. Dig Liver Dis. 2011 Apr; 43(4):286-94.
    View in: PubMed
    Score: 0.057
  18. Cetuximab for metastatic colorectal cancer. N Engl J Med. 2009 Jul 02; 361(1):95; author reply 96-7.
    View in: PubMed
    Score: 0.052
  19. Cetuximab for colorectal cancer. N Engl J Med. 2008 Mar 13; 358(11):1196; author reply 1196-7.
    View in: PubMed
    Score: 0.047
  20. Response of thymoma to cetuximab. Lancet Oncol. 2007 May; 8(5):449-50.
    View in: PubMed
    Score: 0.045
  21. CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors. Nature. 2024 Nov; 635(8038):462-471.
    View in: PubMed
    Score: 0.037
  22. Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: analyses of the CASPIAN phase 3 study. Mol Cancer. 2024 May 30; 23(1):115.
    View in: PubMed
    Score: 0.037
  23. Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN. ESMO Open. 2022 04; 7(2):100408.
    View in: PubMed
    Score: 0.031
  24. Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. J Clin Oncol. 2022 04 20; 40(12):1301-1311.
    View in: PubMed
    Score: 0.031
  25. Patient-Reported Outcomes with Durvalumab With or Without Tremelimumab Versus Standard Chemotherapy as First-Line Treatment of Metastatic Non-Small-Cell Lung Cancer (MYSTIC). Clin Lung Cancer. 2021 07; 22(4):301-312.e8.
    View in: PubMed
    Score: 0.029
  26. Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial. J Thorac Oncol. 2021 05; 16(5):860-867.
    View in: PubMed
    Score: 0.029
  27. Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study. Lung Cancer. 2020 11; 149:46-52.
    View in: PubMed
    Score: 0.028
  28. RELEVENT Trial: Phase II Trial of Ramucirumab, Carboplatin, and Paclitaxel in Previously Untreated Thymic Carcinoma/B3 Thymoma With Area of Carcinoma. Clin Lung Cancer. 2018 09; 19(5):e811-e814.
    View in: PubMed
    Score: 0.024
  29. Immunotherapy: a new standard of care in thoracic malignancies? A summary of the European Respiratory Society research seminar of the Thoracic Oncology Assembly. Eur Respir J. 2018 02; 51(2).
    View in: PubMed
    Score: 0.024
  30. Reply to FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS-mutated tumours in the randomised German AIO study KRK-0306. Ann Oncol. 2012 Oct; 23(10):2771-2772.
    View in: PubMed
    Score: 0.016
  31. Role of cetuximab in the treatment of patients with NSCLC: are we throwing out the baby with the bath water? J Clin Oncol. 2010 Sep 20; 28(27):e467; author reply e468.
    View in: PubMed
    Score: 0.014
  32. Predicting response of molecular targeted therapies: a still possible challenge? Ann Oncol. 2008 May; 19(5):829-30.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.